Kornimate/medical-research-clean huggingface dataset:
mobilization with movement in distal radial fractures

Conditions: Pain; Acute Pain; Mobility Limitation

Summary: distal radius fractures (drf) are the most common upper extremity disorders encountered in clinical practice. with an understanding of the mechanics of distal radius fractures, surgical intervention, and bone healing, the therapist can modify the therapy program according to the patient's individual needs. the therapeutic process is begun in the crucial stage of bone healing during fracture immobilization. by addressing edema reduction and early range of motion of the uninvolved joints, most problems can be avoided before cast or fixator removal. rehabilitation following the immobilization period should focus on regaining wrist movements provided that earlier problems have been addressed properly. during the rehabilitative process, the therapist can incorporate scar management, modalities, joint mobilization, active and passive range of motion, splinting, and strengthening to maximize the patient's functional result. massage and mobilization techniques are used in the treatment of drf due to their analgesic effects. the painless mobilization with movement technique (mwm, developed by brian mulligan) is a manual therapy method applies to correct the limitation of movement in the joint and to relieve pain and functional disorders. many studies have shown that mwm technique provides faster and momentary painless joint movement compared to other physical therapy modalities. the patient group with drf has a large place in the general population and long treatment processes cause both labour loss and economic loss. therefore, this study aimed to examine the effectiveness of mwm technique in cases with distal radius fractures.

in this study, 42 drf patients with age range 18-65 who applied to kırşehir ahi evran university training and research hospital were examined. the individuals included in the study were divided into two groups according to the paired randomization method. these groups were control and intervention groups. traditional physiotherapy methods were applied to the control group, traditional physiotherapy and mwm techniques were applied to the intervention group. traditional physiotherapy methods were included; transcutaneous electrical nerve stimulation (tens), stretching and strengthening exercises. for the evaluation of patients; visual analogue scale (vas), wrist goniometric measurements, grip strength measurement, pinch strength measurement, edema measurement and munich wrist questionnaire (mwq) were used.

Eligibility criteria:
inclusion criteria: * patients with distal radius fracture exclusion criteria: * patients with polytrauma, * open fracture, * ulnar head fracture (excluding ulnar styloid fracture), * history of complex regional pain syndrome, * limited cognitive capacity were excluded

Keywords: pain range of motion
benefits of laparoscopy by single port access for adnexal surgery

Conditions: Adnexal Pathology

Summary: introduction single port access (spa) is a recent laparoscopic technic evaluated in several pathologies. benefits of this technic is poorly reported concerning adnexal surgical procedures. results of both randomised studies including adnexectomy and ovarian cystectomy are discordants. so it seems interesting to conduct a new study about this technic. aim of this study is to compare postoperative pain after laparoscopic surgery for adnexal pathology by spa or classic laparoscopy (cl). materiel and methods we purpose a monocentric-randomised study. inclusion criteria are women over 18 years requiring laparoscopic surgery for adnexal pathology with stratification for procedure (adnexectomy or ovarian cystectomy). after informed consent, patients will be randomised in two groups: laparoscopy with spa and laparoscopy with cl. the main objective is postoperative pain evaluation at 24 hours. secondary objectives are characteristics and perioperative complications, duration of procedure, postoperative quality of life and immediate postoperative pain. we hypothesis laparoscopy with spa reduces postoperative pain at 24 hours of 2 pts (analogic scale 0-10). the estimated size of population number is 54 per group and 108 for the study. expected results we expected a significant decrease of postoperative pain with spa technic. this data will be interesting to promote use of spa technic for adnexal surgery.


Eligibility criteria:
inclusion criteria: presumed benign adnexal disease adnexal pathologies treated between 7:00 am and 10:00 pm signed informed consent patient presenting no contraindication to laparoscopy exclusion criteria: salpingitis and twist annexes. the patient does not fluently read french.
abemaciclib (ly2835219) in men with heavily treated metastatic castration-resistant prostate cancer

Conditions: Metastatic Castration-Resistant Prostate Cancer

Summary: the study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.


Eligibility criteria:
inclusion criteria: * participant must have metastatic prostate cancer for which castration (medical or surgical) is no longer effective (castration-resistant). * participant must have disease spread to soft tissue that is measurable. * participant must have documented evidence of progressive disease by psa test or imaging. * participant must have previously received at least one of the following treatment: abiraterone acetate, apalutamide, darolutamide or enzalutamide. * participant must have previously received chemotherapy with docetaxel and cabazitaxel. * participant must be willing and amenable to undergo a biopsy of tumor tissue (or able to provide adequate archived tumor tissue sample) and to provide blood for research. * participant must have good physical functioning ability and adequate organ function. exclusion criteria: * participant must not have received more than 3 therapy regimens for metastatic castration-resistant prostate cancer (note: gnrha, first-generation antiandrogens (flutamide, nilutamide, or bicalutamide), diethylstilbestrol (des) (or other estrogens), corticosteroids, ketoconazole, and bone loss-prevention will not count as systemic therapy regimens. * participants must not have previously received abemaciclib or any cyclin-dependent kinase (cdk)4 and/or cdk6 inhibitors. * participants must not have serious and/or uncontrolled preexisting medical condition(s) including but not limited to severe renal impairment, severe hepatic impairment, interstitial lung disease (ild)/pneumonitis, severe dyspnea at rest or requiring oxygen therapy or other serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study. * participants must not have, or suspected to have, brain metastasis. * participants must not have untreated spinal cord compression, evidence of spinal metastases with risk of spinal compression or structurally unstable bone lesions suggesting impending fracture.

Keywords: mcrpc cdk4 cdk6 cdk4/6 cdk4&6 inhibitor cdk4/6 inhibitor ly2835219 cyclone 1 cyclone1
decision-making and risk-taking in bulimia

Conditions: Bulimia Nervosa

Summary: this trial is a set of four independent experiments involving for each of them functional and structural mri data acquisition. they aim at investigating decision making mechanisms in bulimia nervosa when participants have to make food or monetary choices under specific conditions that mimic binge eating episodes or kleptomania which are two major symptoms of bulimia nervosa. all experiments are cross sectional studies. each experiment is subdivided into two parts: a first part without any mri data acquisition and during which all the tasks are performed. this part aims at making sure that a behavioral effect is observed before starting mri data acquisition. the second part aims at investigating the neural correlates observed in the first part and additionally, at reproducing the behavioral effects observed in the first part. therefore the first part may be regarded as an independent study as compared to the second part.

each part of each experiment is built of a main task, a set of secondary tasks and questionnaires. only the main task changes from one experiment to another. within each experiment, the only difference between the two parts is that the main task is performed while participants are being scanned in an mri scanner. details of the tasks are provided below. each part of each experiment is performed over one visit only and is a cross sectional study. the visit is dedicated to the tasks. questionnaires may be filled during the visit or at participant's home within the week following the visit for questionnaires which are not assessing participant's state. questionnaires assessing participant's state are filled during the visit at appropriate time. the total number of participants mentioned below is the sum of the planned number of participants within each group, i.e. patients and healthy participants, within each part of each experiment.

Eligibility criteria:
inclusion criteria: * men and women aged 18 to 35 years with bulimia nervosa according to dsm 5 criteria for the patient's group * for the control group, men and women with the same age range being concerned by food intake and their body shape but without any history of eating disorder. * all participants must have signed an informed consent form and be affiliated to the french public health insurance. * for mri scans, all participants must be right handed. exclusion criteria: * antisocial personality disorder, * borderline personality disorder * addiction to alcohol or psychoactive agent, adhd, any psychotic disorder, * obesity of class 1 or 2 * istory of psychiatric disorder for the control group * history of neurological disorder for both groups * intermittent explosive disorder * any counter indication to mri scans for the parts of experiments which take place in the mri scanner.

Keywords: computational psychiatry decision making risk food monetary eating disorder
prospective study of insulin resistance and cardiovascular disease risk during androgen deprivation therapy for prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to find out if androgen deprivation therapy affects insulin, cardiac risk factors such as cholesterol level, and body fat and muscle.

* this is a non-treatment study. this study has no effect on the care the participant will receive. * in addition to the participants routine standard medical appointments they will need to make 2 additional outpatient visits for special testing over 12 weeks. these 2 additional outpatient visits will include the following: 1) urine and blood tests, 2) oral glucose tolerance test (ogtt) 3) body measurements with a tape measure of your arms, legs, and waist and 4) x-ray evaluations (ct scan and bone density test).

Eligibility criteria:
inclusion criteria: * adenocarcinoma of the prostate, clinical stage m0 * about to initiate gnrh agonist therapy * karnofsky performance status 90 or 100 * serum creatinine \< 2.0mg/dl exclusion criteria: * hormone therapy within 12 months * history of diabetes mellitus or glucose intolerance * anabolic agents or metabolic agents known to affect insulin or glucose levels * prior hormone therapy within the past 12 months and planned hormone therapy during the 12 week study (group 2)

Keywords: androgen deprivation therapy insulin resistance
multiple sclerosis patient experience on kesimpta and ocrevus subcutaneous formulation

Conditions: Multiple Sclerosis

Summary: the study aims to compare the experiences, including injection-related reactions (irrs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab sc formulation


Eligibility criteria:
inclusion criteria: 1. ability to use a mobile device or computer with broadband internet access (or data streaming available) 2. ability to read, understand, and respond in english 3. adult aged 18 years of age or over at the time of the survey 4. self-confirmed diagnosis of ms 5. prescribed either omb or ocr sc and will receive their first injection (day 0) followed by completing the study survey between day 1 and day 7 exclusion criteria: 1. participated in an omb or ocr randomized clinical trial 2. previously treated with omb or ocr sc 3. cognitive impairment that impacts the patient's ability to participate in a survey study
cold and warm water for performance recovery

Conditions: Healthy

Summary: the overall aim of this study is, to evaluate the effectiveness of repeated cold- and warm water immersion on performance recovery after muscle damage.

participants perform a muscle-damage protocol, which comprises 5x20 drop jumps. after the exercise protocol is finished, the participants will undergo one of three recovery interventions. cold-water immersion, warm-water immersion or the control-intervention. during the exercise protocol and the recovery intervention following parameters will be assessed: blood oxygenation, muscle oxygenation, heart-rate, skin temperature and core temperature. then, performance recovery will be assessed during the following 72 hrs (in a 24 hrs interval). at each time-point, following measurements will be conducted: vertical-jump performance, maximum voluntary isometric contraction of the m.quadriceps femoris muscle, muscle swelling and delayed-onset of muscle soreness.

Eligibility criteria:
inclusion criteria: * healthy participants * no surgeries * no previous injuries * anticonceptiva allowed exclusion criteria: * acute injuries or current pain situations * cryophobia * fear * pregnancy * raynaud syndrome * medication intake

Keywords: cold water immersion warm water immersion muscle damage recovery
effects of teduglutide on cardiac repolarisation and conduction in healthy male and female volunteers

Conditions: Healthy

Summary: the primary objective of this trial is to investigate if teduglutide has an effect on cardiac repolarisation (qt, qtc interval). secondary objectives are the investigation of possible effects on heart rate and cardiac conduction (rr and pr intervals, qrs duration), pharmacokinetics and safety and tolerability in healthy subjects, and to determine the effect of the positive control, moxifloxacin, for sensitivity analysis. the trial will consist of a screening and a treatment phase of four treatment periods. there is a washout period of at least 7 days and 4 weeks at maximum between administrations. the expected total trial duration for the individual subject will be about 7 weeks (maximum 17) weeks.


Eligibility criteria:
inclusion criteria: * healthy male or female volunteers * normal body weight (body mass index within ≥18 and 29 kg/m2 (inclusive) and a body weight \>50 kg (females) and \>60 kg (males).

Keywords: thorough qtc-study short bowel syndrome cardiac safety
isokinetic exercises in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the investigators evaluated the effects of isokinetic muscle strengthening exercises of the quadriceps and hamstring on muscle strength, joint position sense, pain, kinesiophobia and quality of life in patients with multiple sclerosis.

objective: to evaluate the effects of isokinetic exercises on muscle strength, knee joint position sense, pain, kinesiophobia, and quality of life in patients with multiple sclerosis. design: randomized controlled trial. setting: outpatient clinic. participants: fifty patients with multiple sclerosis. interventions: fifty patients who met the inclusion criteria were randomized to an isokinetic exercise (n:25) or home exercise programme (n:25). sequentially numbered opaque envelopes were used for randomization. outcome measures: the outcome measures were the peak torque/body mass index of quadriceps and hamstring muscles at 60°/s and 180°/s velocities, the hamstring/quadriceps ratios at the same velocities, absolute angular errors of the 15°, 45°, and 60° and the mean absolute angular error of joint position sense of the less and more affected knees, and the scores of multiple sclerosis quality of life-54, visual analogue scale, and tampa scale of kinesiophobia.

Eligibility criteria:
inclusion criteria: * definite relapsing remitting ms and secondary progressive ms diagnosis * mild and moderate ms determined by kurtzke expanded disability status scale (edss) scores below 6.5 * a disease duration of more than one year. exclusion criteria: * having an acute exacerbation within the last three months * intravenous pulse steroid therapy in the last four weeks * grade 3-4 spasticity according to the modified ashworth scale * severe vision impairment * severe fatigue and depression * past knee surgery * other neurologic diseases * systemic diseases * pregnancy * having received an exercise program within the last four weeks.

Keywords: multiple sclerosis isokinetic exercises joint position sense kinesiophobia
effects of andriol testocaps in symptomatic late-onset hypogonadism (43203)

Conditions: Hypogonadism; Androgens

Summary: in this study we have evaluated the effects of three different doses of oral testosterone undecanoate in aging men presenting with a combination of symptoms suggestive of hypogonadism and low blood levels of the male hormone testosterone. specifically, we have studied the effects on: * symptoms suggestive of low testosterone levels * blood testosterone and other hormone levels * bone mass * muscle mass and fat mass * muscle strength * prostate * lipids, hematocrit


Eligibility criteria:
inclusion criteria: * subjects were at least 50 years of age * a body mass index (bmi) between 18 and 34 kg/m\^2 * symptoms of androgen deficiency (as indicated by a positive androgen deficiency in aging males (adam) questionnaire) * calculated free testosterone measurement of \<0.26 nmol/l in the morning exclusion criteria: * history or current diagnosis of breast or prostate cancer * any clinically significant abnormal finding on physical examination including the prostate * clinical symptoms of obstructive benign prostate hyperplasia (international prostate symptom score (ipss) \>14) * prostate specific antigen (psa) level \> 4 ng/ml at screening * cause of androgen deficiency other than aging, e.g. 'classical' diagnosis of primary or secondary hypogonadism * hyperprolactinaemia or treatment with prolactin-lowering drugs * history of known chronic polycythemia and/or hematocrit \>50% at screening * history or presence of severe sleep apnea * unstable or untreated endocrine disorders * history or presence of clinically significant depression or other psychiatric disorder or any clinically relevant cardiovascular, cerebrovascular, endocrine, hepatic, renal or hematological disease, thromboembolism/thrombosis etc. which, in the opinion of the investigator, might compromise the subject's participation in the trial * use of medication that would interfere with the efficacy and safety objectives of the trial
dexmedetomidine vs dexamethasone in popliteal nerve block

Conditions: Ankle Disease; Ankle Injuries and Disorders; Foot Injury; Foot Diseases

Summary: effect of perineural dexmedetomidine vs. dexamethasone on the duration of popliteal nerve block for anesthesia after pediatric ankle/foot surgery.

this study is proposed to explore the effect of systemic dexamethasone on the duration of popliteal block for analgesia after pediatric ankle surgery. after ankle/foot surgery, children need good analgesia. peripheral nerve blocks have provided a safe, effective method to control early postoperative pain when symptoms are most severe. the safety of local anaesthesia is essential in children due to the much lower toxicity threshold of local anaesthetics. an effective adjuvant, such as dexamethasone, could allow for a higher dilution of local anaesthetics while maintaining and enhancing their analgesic effect. there is considerable research where intravenous and perineural dexamethasone use has been compared in adults. however, there is a massive lack of research regarding children. in this study, investigators compare perineural dexmedetomidine and dexamethasone. group 2 will have dexamethasone in a 0.1mg/kg dose, and group 2 will have dexmedetomidine in a 0.5 ug/kg dose added to the local anaesthetic in peripheral nerve block. the investigator's goal is to find which perineural adjuvant, dexamethasone or dexmedetomidine, covers the need for good pain relief and fast recovery postoperatively.

Eligibility criteria:
inclusion criteria: * children scheduled for foot/ankle surgery * body weight \> 5kg exclusion criteria: * infection at the site of the regional blockade * coagulation disorders * immunodeficiency * asa= or \>4 * steroid medication in regular use
effects of milk probiotics intervention on blood glucose control middle-aged and elderly people with pre-diabetes

Conditions: Pre-biabetes

Summary: this study aims to conduct a 8-week probiotics intervention involving for middle-aged and elderly individuals with pre-diabetes, assessing its impact on blood glucose control in comparison to placebo


Eligibility criteria:
inclusion criteria: 1. age between 40 and 75 years, regardless of gender. 2. impaired fasting glucose (5.6 mmol/l ≤ fpg \< 6.9 mmol/l) or glycated hemoglobin (hba1c) between 5.7-6.4% (39-47 mmol/mol). 3. resided in guangzhou for the past six months and no plans to relocate or travel outside the city in the next month. 4. signed informed consent form and voluntarily agreed to participate in the project. exclusion criteria: 1. patients with a confirmed diagnosis of diabetes who are currently taking glucose-lowering medications (e.g., insulin, glp-1 receptor agonists, or sglt2 inhibitors). 2. individuals with lactose intolerance or dairy product intolerance. 3. pregnant, planning to become pregnant within the next three months, or currently breastfeeding. 4. weight change \> 5% in the past three months or plans to lose weight or change dietary habits. 5. alcohol consumption \> 40g/day. 6. individuals with communication barriers, cognitive impairments, or other conditions that may prevent them from completing the study procedures. 7. severe diseases that may affect participation in the study, including but not limited to endocrine disorders, severe cardiovascular or cerebrovascular diseases, cancer, metabolic diseases, etc. 8. participation in or current involvement in other clinical trials within the past three months. 9. no use of antibiotic medications within the past three months.